The Pharma Data

NOVEMBER 22, 2020

Founded in 2007, Alzprotect is a French Lille-based company created by Dr. André Delacourte, one of the pioneers of research on Alzheimer’s disease, and Dr. Patricia Melnyk, expert in medicinal chemistry, in collaboration with University of Lille and Inserm. About XERYS. View source version on businesswire.com: [link]. Source link.

Drugs 40

Drugs Protein Bioavailability Development 40

The Pharma Data

AUGUST 16, 2021

Lebrikizumab is a novel monoclonal antibody (mAb) that binds soluble IL-13 with high affinity, has high bioavailability, a long half-life and blocks IL-13 signaling. Fast Track designation is granted for a medicine that is intended to treat a serious condition and data demonstrate the potential to address an unmet medical need.

Trials 40

Trials Dermatology Bioavailability Medicine 40

Delveinsight

JULY 30, 2020

Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands. A novel, brain penetrant, orally bioavailable and selective PPAR?

Hormones 52

Hormones Marketing Gene Trials 52

The Pharma Data

NOVEMBER 19, 2020

Program focused on inhibitors of SARS-CoV-2 main protease, a highly conserved protein essential for viral replication. These compounds have demonstrated high potency in inhibiting the activity of the M pro protease as well as promising oral bioavailability and blood plasma levels in animal studies.

Development 40

Development Bioavailability Production Drugs 40

XTalks

AUGUST 30, 2022

We know that a lot of different pathologies, especially as we’ve entered the era of molecular medicine and gene therapies, cause many of the same symptoms and work through final common pathways. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? Next Steps for Targeted CNS Delivery.

Trials 83

Trials Drug Delivery Drugs Gene 83

Delveinsight

SEPTEMBER 8, 2021

The risk factors for SLE include the medicines that induce lupus, age, race/ethnicity, and family history. It is also available as a generic medicine. Baricitinib, also known as LY3009104 or INCB028050 , is a novel orally bioavailable inhibitor of the tyrosine-protein kinase JAK1 or JAK2. Baricitinib (INCB-028050).

Marketing 52

Marketing Sales FDA Approval Antibody 52

XTalks

AUGUST 8, 2024

Dr. Dieterich elaborated on the critical aspects of each component: “There’s the protein part, a small molecule and then there’s the linker part in the middle.” Dieterich discussed the potential of applying ADC techniques to AOCs, which use oligonucleotides to interfere with mRNA and, thus, protein production.

Development 64

Development Medicine Antibody Protein 64

Roots Analysis

OCTOBER 2, 2023

Owing to their unique size and physicochemical properties ( surface roughness, surface area, surface energy, crystal structure and shape ), nanoparticles can be widely used as a contrasting agent in medical imaging, a vesicle to cross the blood-brain barrier and a carrier for targeted delivery of genes / drugs, proteins, vaccines and antibiotics.

Drug Delivery 40

Drug Delivery Drugs Bioavailability Development 40

The Pharma Data

DECEMBER 9, 2020

Li is a prominent neuroscientist and former professor at Johns Hopkins Medicine. Artificial intelligence holds immense promise to catalyze the development of the next generation of highly selective, orally bioavailable molecules, with reduced side effects, for the most impactful drug targets,” Feinberg said at the time of the launch.

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

The Pharma Data

OCTOBER 9, 2021

“The treatment of CMV in patients who have undergone a solid organ or stem cell transplant is complicated, especially in patients who have failed standard treatment and who may be at risk for side effects from currently available medications,” said Dr. Emily Blumberg, Director, Transplant Infectious Diseases, Penn Medicine.

Drugs 52

Drugs Genotype Bioavailability Medicine 52

XTalks

MARCH 24, 2025

Over time, this leads to proteinuria, where protein leaks into the urine, and eventually to kidney failure. Last month, the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a positive opinion on Fabhalta for C3G. Regulatory reviews in China and Japan are underway.

Bioavailability 71

Bioavailability Immune Response Protein Bacteria 71